US EditionPublished • loading... • Updated
Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltra
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Zai Lab shares Phase 1 data for lung cancer drug that could spar with Amgen’s Imdelltra
Zai Lab on Friday reported updated early-stage data for its closely-watched ADC candidate that could compete with Amgen’s Imdelltra. Both drugs target the DLL3 protein and are designed to treat extensive-stage small cell lung cancer ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
